22nd Century Group (NYSEAMERICAN:XXII) was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued on Friday, March 29th, TheStreetRatingsTable reports.
Separately, Chardan Capital reiterated a “buy” rating and set a $11.50 price target on shares of 22nd Century Group in a research report on Friday, March 15th.
Shares of NYSEAMERICAN XXII traded up $0.06 during trading on Friday, reaching $1.98. The stock had a trading volume of 1,368,090 shares, compared to its average volume of 1,778,706. 22nd Century Group has a one year low of $1.58 and a one year high of $3.29.
A number of large investors have recently bought and sold shares of XXII. Mercer Global Advisors Inc. ADV acquired a new position in 22nd Century Group in the 1st quarter worth about $28,000. HRT Financial LLC acquired a new position in 22nd Century Group in the 4th quarter worth about $33,000. D. E. Shaw & Co. Inc. acquired a new position in 22nd Century Group in the 4th quarter worth about $33,000. GSA Capital Partners LLP acquired a new position in 22nd Century Group in the 4th quarter worth about $38,000. Finally, Principal Financial Group Inc. acquired a new position in 22nd Century Group in the 4th quarter worth about $40,000.
About 22nd Century Group
22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The company offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.
Recommended Story: How to interpret a stock’s beta number
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.